These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 19777259)

  • 1. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.
    Li YH; Luo HY; Wang FH; Wang ZQ; Qiu MZ; Shi YX; Xiang XJ; Chen XQ; He YJ; Xu RH
    J Cancer Res Clin Oncol; 2010 Apr; 136(4):503-10. PubMed ID: 19777259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
    Díaz-Rubio E; Gómez-España A; Massutí B; Sastre J; Abad A; Valladares M; Rivera F; Safont MJ; Martínez de Prado P; Gallén M; González E; Marcuello E; Benavides M; Fernández-Martos C; Losa F; Escudero P; Arrivi A; Cervantes A; Dueñas R; López-Ladrón A; Lacasta A; Llanos M; Tabernero JM; Antón A; Aranda E;
    Oncologist; 2012; 17(1):15-25. PubMed ID: 22234633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
    J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer.
    Yaman E; Uner A; Er O; Coskun U; Buyukberber S; Dikilitas M; Polat M; Yamac D; Kaya AO; Yildiz R; Ozturk B; Benekli M
    Med Oncol; 2007; 24(4):431-5. PubMed ID: 17917094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.
    Pilancı KN; Saglam S; Okyar A; Yucel S; Pala-Kara Z; Ordu C; Namal E; Ciftci R; Iner-Koksal U; Kaytan-Saglam E
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):143-50. PubMed ID: 27270460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
    Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
    Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
    Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
    Díaz-Rubio E; Tabernero J; Gómez-España A; Massutí B; Sastre J; Chaves M; Abad A; Carrato A; Queralt B; Reina JJ; Maurel J; González-Flores E; Aparicio J; Rivera F; Losa F; Aranda E;
    J Clin Oncol; 2007 Sep; 25(27):4224-30. PubMed ID: 17548839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.
    Yalcin S; Uslu R; Dane F; Yilmaz U; Zengin N; Buyukunal E; Buyukberber S; Camci C; Sencan O; Kilickap S; Ozdener F; Cevik D
    Oncology; 2013; 85(6):328-35. PubMed ID: 24247559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.
    Kim C; Lee JL; Ryu MH; Chang HM; Kim TW; Lim HY; Kang HJ; Park YS; Ryoo BY; Kang YK
    Invest New Drugs; 2011 Apr; 29(2):366-73. PubMed ID: 19997960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
    Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).
    Hurwitz H; Mitchell EP; Cartwright T; Kwok A; Hu S; McKenna E; Patt YZ
    Oncologist; 2012; 17(7):937-46. PubMed ID: 22622147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
    Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
    Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
    Kim SH; Shin SJ; Kim SY; Lee SH; Park YS; Park SH; Lee KH; Kim TW; Hong YS; Ahn JB
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):91-7. PubMed ID: 21607556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
    Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Sato A; Koizumi W; Mizunuma N; Takiuchi H
    Jpn J Clin Oncol; 2010 Oct; 40(10):913-20. PubMed ID: 20462981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
    Li W; Xu J; Shen L; Liu T; Guo W; Zhang W; Chen Z; Zhu X; Li J
    BMC Cancer; 2014 Dec; 14():986. PubMed ID: 25527007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
    Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D
    Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
    Twelves CJ; Butts CA; Cassidy J; Conroy T; Braud Fd; Diaz-Rubio E; Tabernero JM; Schoffski P; Figer A; Brunet R; Grossmann J; Sobrero AF; Van Cutsem EJ
    Clin Colorectal Cancer; 2005 Jul; 5(2):101-7. PubMed ID: 16098250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
    de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
    Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
    Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
    J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.